Macroimmunology and immunotherapy of cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Immunotherapy

• Publication date

  2009-04-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/imt.09.6PMID 20635957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4 T cell cooperation is required for the in vivo activation of CD4 T cells.

  2009cited by this paper
• Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer

  2008cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• CD4 T cells: fates, functions, and faults.

  2008cited by this paper
• Immunological aspects of cancer chemotherapy

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage

  2007cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

  2006cited by this paper
• Regulatory T cells in cancer.

  2006cited by this paper
• Clinical significance of serum Th1‐, Th2‐ and regulatory T cells‐associated cytokines in adult T‐cell leukemia/lymphoma: High interleukin‐5 and ‐10 levels are significant unfavorable prognostic factors

  2006cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1‐type immune response

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A)

  2006cited by this paper
• Regulatory T cells in immune surveillance and treatment of cancer.

  2006cited by this paper
• Tumor-specific Transplantation Antigens :

  2006cited by this paper
• Increasing the foreignness of an antigen, by coupling a second and foreign antigen to it, increases the T helper type 2 component of the immune response to the first antigen

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells

  2004cited by this paper
• Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

  2004cited by this paper
• Modulating Th1/Th2 responses with microbes, dendritic cells, and pathogen recognition receptors

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

  2003cited by this paper
• Tumour‐induced polarization of tumour vaccine‐draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

  2003cited by this paper
• Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

  2003cited by this paper
• Tumor‐specific shared antigenic peptides recognized by human T cells

  2002cited by this paper
• More antigen‐dependent CD4+ T cell / CD4+ T cell interactions are required for the primary generation of Th2 than of Th1 cells

  2001cited by this paper
• Toll-like receptors control activation of adaptive immune responses

  2001cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• A case for a neonatal, low-dose BCG vaccination trial.

  2001cited by this paper
• Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

  2001cited by this paper
• Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure.

  2001cited by this paper
• Anti‐IL‐4 antibody therapy causes regression of chronic lesions caused by medium‐dose Leishmania major infection in BALB/c mice

  2001cited by this paper
• Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections

  2001cited by this paper
• Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

  2001cited by this paper
• Functional cooperation between T helper cell determinants.

  2000cited by this paper
• A two-step, two-signal model for the primary activation of precursor helper T cells.

  1999cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

  1999cited by this paper
• Mycobacterial Dose Defines the Th1/Th2 Nature of the Immune Response Independently of Whether Immunization Is Administered by the Intravenous, Subcutaneous, or Intradermal Route

  1998cited by this paper
• T helper 2-dominant antilymphoma immune response is associated with fatal outcome.

  1997cited by this paper
• Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

  1997cited by this paper
• Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge

  1996cited by this paper
• Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma

  1996cited by this paper
• Predominant expression of invariant Vα14+ TCR α chain in NK1.1+ T cell populations

  1995cited by this paper
• T cell genetic background determines default T helper phenotype development in vitro

  1995cited by this paper
• Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations.

  1995cited by this paper
• Tumor antigens recognized by T lymphocytes.

  1994cited by this paper
• A strategy for prophylactic vaccination against HIV.

  1993cited by this paper
• Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.

  1992cited by this paper
• A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.

  1992cited by this paper
• TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

  1989cited by this paper
• Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

  1989cited by this paper
• Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.

  1987cited by this paper
• A cascade of T-T interactions, mediated by the linked recognition of antigen, in the induction of T cells able to help delayed-type hypersensitivity responses.

  1986cited by this paper
• Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells

  1986cited by this paper
• Down-regulation of the antitumor immune response.

  1985cited by this paper
• Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice.

  1985cited by this paper
• The murine antitumor immune response and its therapeutic manipulation.

  1984cited by this paper
• Specificity of the T Cells That Mediate and Suppress Adoptive Immunotherapy of Established Tumors

  1984cited by this paper
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• Regulation of the class of immune response induced by antigen. I. Specific T cells switch the in vivo response from a cell-mediated to humoral mode.

  1983cited by this paper
• In vitro analysis of the cellular interactions between unprimed lymphocytes responsible for determining the class of response an antigen induces: specific T cells switch a cell-mediated response to a humoral response.

  1983cited by this paper
• Concomitant tumor immunity and the resistance to a second tumor challenge.

  1983cited by this paper
• T cells cooperating in the induction of delayed-type hypersensitivity act via the linked recognition of antigenic determinants

  1982cited by this paper
• Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c nude mice.

  1981cited by this paper
• Significance and mechanisms of cellular regulation of the immune response.

  1981cited by this paper
• Significance and mechanisms of cellular regulation of the immune response.

  1981cited by this paper
• Discrimination of suppressor T cells of humoral and cell-mediated immunity by anti-Ly and anti-Ia sera.

  1977cited by this paper
• Passive immunotherapy of cancer in animals and man.

  1977cited by this paper
• Influence of the antigenicity of target cells on the antibody-mediated cytotoxicity of nonsensitized lymphocytes.

  1975cited by this paper
• On the control between cell-mediated, IgM and IgG immunity.

  1974cited by this paper
• Effect of antigen density on complement-mediated lysis, T-cell-mediated killing, and antigenic modulation.

  1974cited by this paper
• POTENTIATION OF T-CELL-MEDIATED IMMUNITY BY SELECTIVE SUPPRESSION OF ANTIBODY FORMATION WITH CYCLOPHOSPHAMIDE

  1974cited by this paper
• The Relationship Between Humoral and Cell‐Mediated Immunity

  1972cited by this paper
• MACROPHAGE-DIGESTED ANTIGEN AS INDUCER OF DELAYED HYPERSENSITIVITY

  1971cited by this paper
• Immunological enhancement as studied by cell culture techniques.

  1970cited by this paper
• Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture.

  1968cited by this paper
• Evidence for an immunological reaction of the host directed against its own actively growing primary tumor.

  1966cited by this paper
• Selective and specific inhibition of 24 hour skin reactions in the guinea-pig. I. Immune deviation: description of the phenomenon and the effect of splenectomy.

  1965cited by this paper
• Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

  1960cited by this paper
• OCCURRENCE OF DELAYED HYPERSENSITIVITY DURING THE DEVELOPMENT OF ARTHUS TYPE HYPERSENSITIVITY

  1958cited by this paper
• Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.

  1953cited by this paper
• Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.

  1953cited by this paper
• Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line

  1943cited by this paper
• Regulation of the immune response

  year unknowncited by this paper

• The immune microenvironment of lung adenocarcinoma featured with ground‐glass nodules

  2024cites this paper
• T cell dysfunctions in myelodysplastic syndromes.

  2024cites this paper
• Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model

  2023cites this paper
• On antigen‐specific signals, immune class regulation and energetics: Report III from the workshops on foundational concepts of immune regulation

  2023cites this paper
• NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

  2022cites this paper
• Roles of CD4+ T cells as mediators of antitumor immunity

  2022cites this paper
• The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed

  2021cites this paper
• On the Mechanism Determining the Th1/Th2 Phenotype of an Immune Response, and its Pertinence to Strategies for the Prevention, and Treatment, of Certain Infectious Diseases

  2014cites this paper
• Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

  2011cites this paper
• Immunization of newborn and adult mice with low numbers of BCG leads to Th1 responses, Th1 imprints and enhanced protection upon BCG challenge.

  2010cites this paper